Comparison of Rocket Pharmaceuticals Inc. (RCKT) and Vical Incorporated (NASDAQ:VICL)

We are contrasting Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) and Vical Incorporated (NASDAQ:VICL) on their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations. They both are Biotechnology companies, competing one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Rocket Pharmaceuticals Inc. N/A 0.00 78.63M -1.89 0.00
Vical Incorporated N/A 21.66 14.56M -0.67 0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Rocket Pharmaceuticals Inc. and Vical Incorporated.

Profitability

Table 2 shows us Rocket Pharmaceuticals Inc. and Vical Incorporated’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Rocket Pharmaceuticals Inc. 0.00% -46.8% -35.1%
Vical Incorporated 0.00% -29.4% -27.6%

Risk and Volatility

Rocket Pharmaceuticals Inc.’s volatility measures that it’s 205.00% more volatile than Standard and Poor’s 500 due to its 3.05 beta. Vical Incorporated on the other hand, has 0.54 beta which makes it 46.00% less volatile compared to Standard and Poor’s 500.

Liquidity

The Current Ratio and Quick Ratio of Rocket Pharmaceuticals Inc. are 9.7 and 9.7 respectively. Its competitor Vical Incorporated’s Current Ratio is 18.4 and its Quick Ratio is 18.4. Vical Incorporated can pay off short and long-term obligations better than Rocket Pharmaceuticals Inc.

Insider and Institutional Ownership

Roughly 85.9% of Rocket Pharmaceuticals Inc. shares are held by institutional investors while 38.6% of Vical Incorporated are owned by institutional investors. 1.8% are Rocket Pharmaceuticals Inc.’s share held by insiders. Comparatively, Vical Incorporated has 0.97% of it’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Rocket Pharmaceuticals Inc. -9.18% -3.64% 14.65% 0.94% -9.13% 16.19%
Vical Incorporated -1.41% -3.39% 15.15% -14.29% -32.94% -3.39%

For the past year Rocket Pharmaceuticals Inc. has 16.19% stronger performance while Vical Incorporated has -3.39% weaker performance.

Summary

Vical Incorporated beats on 6 of the 7 factors Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under preclinical development. The company has collaboration agreements with Lund University, Sweden; and Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas. The company is headquartered in New York, New York.

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It is developing various DNA-based vaccines and other therapeutics, such as VCL-HB01 therapeutic vaccine for herpes simplex virus-2 that is in Phase II clinical trial to prevent and protect against lesion recurrence; VL-2397 antifungal program, which is in Phase I clinical trial for the treatment of invasive fungal infections; and CyMVectin prophylactic vaccine for CMV that is in preclinical stage for the prevention of fetal transmission during pregnancy. The company also engages in contract manufacturing of plasmid investigational products for various clients. It has collaborations with Astellas to develop and commercialize certain products, including ASP0113 for the control and prevention of CMV infection in immunocompromised patients; and Merial for use of the companyÂ’s core DNA delivery technology in a therapeutic vaccine designed to aid in extending survival time of dogs with oral melanoma. It also has a license agreement with Astellas to develop and commercialize novel antifungal candidate. The company was founded in 1987 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.